Therapeutic Areas

LEO Pharma has been working to improve patients' lives with dermatological products for more than 50 years. Today, we continue to be passionate about understanding the challenges that patients and healthcare professionals encounter.


Psoriasis is a chronic, systemic inflammatory skin disease that is estimated to affect about 3.2% of the U.S. population. (1) About 80% of patients are affected by mild or moderate plaque psoriasis, the most common clinical form of psoriasis. (2) Topical treatments are first-line therapies for the majority of patients.

Atopic Dermatitis

Atopic Dermatitis (AD) is a common type of eczema that affects up to five percent of adults across the United States, Canada, Europe and Japan. (3)  It is a chronic, relapsing skin disease, characterized by severe itch, dry skin, persistent immune-mediated inflammation, and skin barrier defects. (4) AD has a significant, negative impact on patients’ well-being, primarily due to the intense itch which leads to disrupted sleep and other negative consequences. (4) There is currently a high unmet need for long-term efficacious and well-tolerated treatment options in atopic dermatitis. (5)


Rosacea is a chronic and common skin disorder that primarily affects the central face, causing visible blood vessels and redness, with the potential to also produce small red bumps, filled with pus. (6) Signs and symptoms may flare up for a period of weeks to months and then diminish for a while. Rosacea can be mistaken for acne, an allergic reaction or other skin problems. (6) Rosacea can occur in anyone. But it most commonly affects middle-aged women with fair skin. (6)

Actinic Keratosis

Actinic keratosis is a condition of skin lesions, the majority of which are caused by UV exposure (usually from the sun) in fair-skinned people. Lesions are often red, scaly and may initially be mistaken for a rash or other skin irritation, but do not improve over time. The number of patients with actinic keratosis is both large and rapidly growing, especially in Europe, the U.S. and Australia, with the American Academy of Dermatology estimating that 60% of predisposed persons older than 40 have at least one actinic keratosis lesion. (7,8) People at high risk are often over the age of 40 and tend to have fair skin and a history of sun exposure. (7)


  1. Rachakonda, T., Schupp, C., and Armstrong, A.W. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014; 70: 512–516.
  2. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol; 2008 May;58(5):826-50.
  3. Barbarot S, Auziere S et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi: 10.1111/all.13401.
  4. Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016; 387:1109-22.
  5. Q&A with Dr. Silverberg. Ask the Presenter - Conference Report. AJMC 2016.
  6. Clinic. Rosacea. Accessible at Accessed September 2019. 
  7. Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Goltz RW, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995;32(1):95-8.
  8. Ko CJ. Actinic keratosis: facts and controversies. Clin Dermatol 2010;28(3):249-53.